CA9 and prostate cancer: The analysis of protein expression in distinct pathological groups (by stage, differentiation score and PSA serum levels at diagnosis), which are predictive of prostate cancer aggressiveness, showed at most only trends for increased expression of VEGFR2 in carcinomas with Gleason >7 or patients with PSA > 10 ng/mL, and of CAIX in patients with PSA > 10 ng/mL.